496 reports of this reaction
1.3% of all ACETAMINOPHEN, ASPIRIN, AND CAFFEINE reports
#14 most reported adverse reaction
OFF LABEL USE is the #14 most commonly reported adverse reaction for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, manufactured by Haleon US Holdings LLC. There are 496 FDA adverse event reports linking ACETAMINOPHEN, ASPIRIN, AND CAFFEINE to OFF LABEL USE. This represents approximately 1.3% of all 37,042 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, ASPIRIN, AND CAFFEINE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 496 FDA reports for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 1.3% of all adverse event reports for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, making it a notable side effect.
If you experience off label use while taking ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.